Iopamiro 370 mg/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iopamiro 370 mg/ml raztopina za injiciranje

bracco imaging s.p.a. - jod - raztopina za injiciranje - jod 370 mg / 1 ml jopamidol - jopamidol

Iomeron 350 mg/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iomeron 350 mg/ml raztopina za injiciranje

bracco imaging s.p.a. - jod - raztopina za injiciranje - jod 350 mg / 1 ml jomeprol - jomeprol

Iomeron 400 mg/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iomeron 400 mg/ml raztopina za injiciranje

bracco imaging s.p.a. - jod - raztopina za injiciranje - jod 400 mg / 1 ml jomeprol - jomeprol

Iomeron 300 mg/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iomeron 300 mg/ml raztopina za injiciranje

bracco imaging s.p.a. - jod - raztopina za injiciranje - jod 300 mg / 1 ml jomeprol - jomeprol

Iomeron 350 mg/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iomeron 350 mg/ml raztopina za injiciranje

bracco imaging s.p.a. - jod - raztopina za injiciranje - jod 350 mg / 1 ml jomeprol - jomeprol

MultiHance 0,5 mmol/ml raztopina za injiciranje Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

multihance 0,5 mmol/ml raztopina za injiciranje

bracco imaging s.p.a. - gadobenska kislina - raztopina za injiciranje - gadobenska kislina 334 mg / 1 ml - gadobenska kislina

Yescarta Európai Unió - szlovén - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.